Bifogade filer
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
SECOND QUARTER 2023 (APR – JUN)
Net sales amounted to SEK 216.2 million (188.2), corresponding to an increase of 15 percent compared with the corresponding period in the preceding year.
License revenue amounted to SEK 75.7 million (45.4) and accounted for 35 percent of net sales (24).
Operating profit amounted to SEK 47.5 million (38.6).
Net profit amounted to SEK 38.8 million (26.5), corresponding to earnings per share of SEK 0.76 (0.52).
Cash flow from operating activities amounted to SEK 85.1 million (30.4). As of June 30, 2023, cash and cash equivalents amounted to SEK 574.4 million (362.3).
FIRST HALF OF 2023 (JAN – JUN)
Net sales amounted to SEK 445.3 million (347.4), corresponding to an increase of 28 percent compared with the corresponding period in the preceding year.
Operating profit amounted to SEK 100.8 million (58.6).
Net profit amounted to SEK 88.6 million (43.0), corresponding to earnings per share of SEK 1.74 (0.85).
Cash flow from operating activities amounted to SEK 145.6 million (41.5).
Gothenburg, Sweden, August 24, 2023
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.